Abiraterone delays metastatic prostate cancer growth by 18 months, extends survival
Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 ...
Jun 5, 2017
0
0